Increased morbidity and mortality in murine cytomegalovirusinfected mice following allogeneic bone marrow transplant is associated with reduced surface decay accelerating factor expression

Clinical and Experimental Immunology

Volumn 162, Issue 2, 2010, Pages 379-391

  El Amouri, I S ^a   Bani Ahmad, M ^a   Tang Feldman, Y ^b   Lin, F ^c   Ko, C ^a   Pomeroy, C ^b   Oakley, O R ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

CD55; Complement regulatory proteins; DAF; GFP MCMV (RVG102); ICAM 1; MCMV; VCAM 1

Indexed keywords

DECAY ACCELERATING FACTOR; GAMMA INTERFERON;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD8+ T LYMPHOCYTE; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; FEMALE; IMMUNE MEDIATED INJURY; KNOCKOUT MOUSE; LUNG; LYMPHOCYTE PROLIFERATION; MORBIDITY; MORTALITY; MOUSE; NONHUMAN; PLAQUE FORMING CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; VIRUS REACTIVATION; WILD TYPE;

ANIMALS; ANTIGENS, CD55; BODY WEIGHT; BONE MARROW TRANSPLANTATION; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL COUNT; COMPLEMENT ACTIVATION; COMPLEMENT C3A; COMPLEMENT C3D; CYTOMEGALOVIRUS INFECTIONS; FEMALE; IMMEDIATE-EARLY PROTEINS; INTERCELLULAR ADHESION MOLECULE-1; INTERFERON-GAMMA; LUNG; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS; VASCULAR CELL ADHESION MOLECULE-1;

EID: 78649237448     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2010.04241.x     Document Type: Article

References (69)

1. Nagafuji K, Eto T, Hayashi S, Tokunaga Y, Gondo H, Niho Y. Fatal cytomegalovirus interstitial pneumonia following autologous peripheral blood stem cell transplantation. Fukuoka Bone Marrow Transplantation Group. Bone Marrow Transplant 1998; 21:301-3.
2. Nomura F, Shimokata K, Sakai S, Yamauchi T, Kodera Y, Saito H. Cytomegalovirus pneumonitis occurring after allogeneic bone marrow transplantation: a study of 106 recipients. Jpn J Med 1990; 29:595-602.
3. Rege K, Mehta J, Treleaven J et al. Fatal pneumococcal infections following allogeneic bonemarrow transplant. Bone Marrow Transplant 1994; 14:903-6.
4. Roychowdhury M, Pambuccian SE, Aslan DL et al. Pulmonary complications after bone marrow transplantation: an autopsy study from a large transplantation center. Arch Pathol Lab Med 2005; 129:366-71.
5. Tsinontides AC, Bechtel TP. Cytomegalovirus prophylaxis and treatment following bone marrow transplantation. Ann Pharmacother 1996; 30:1277-90.
6. Emery VC. Investigation of CMV disease in immunocompromised patients. J Clin Pathol 2001; 54:84-8.
7. Bleggi-Torres LF, deMedeiros BC,Werner B et al. Neuropathological findings after bone marrow transplantation: an autopsy study of 180 cases. Bone Marrow Transplant 2000; 25:301-7.
8. Castagnola E, Cappelli B, Erba D, Rabagliati A, Lanino E, Dini G. Cytomegalovirus infection after bone marrow transplantation in children. Hum Immunol 2004; 65:416-22.
9. Chandrasekar PH, Weinmann A, Shearer C. Autopsy-identified infections among bone marrow transplant recipients: a clinicopathologic study of 56 patients. Bone Marrow Transplantation Team. Bone Marrow Transplant 1995; 16:675-81.
10. Couriel D, Canosa J, Engler H, Collins A, Dunbar C, Barrett AJ. Early reactivation of cytomegalovirus and high risk of interstitial pneumonitis following T-depleted BMT for adults with hematological malignancies. Bone Marrow Transplant 1996; 18:347-53.
11. Carroll MC. The complement system in regulation of adaptive immunity. Nat Immunol 2004; 5:981-6.
12. Carroll MC, Prodeus AP. Linkages of innate and adaptive immunity. Curr Opin Immunol 1998; 10:36-40.
13. Nielsen CH, Fischer EM, Leslie RG. The role of complement in the acquired immune response. Immunology 2000; 100:4-12.
14. Nielsen CH, Leslie RG. Complement's participation in acquired immunity. J Leukoc Biol 2002; 72:249-61.
15. Ochsenbein AF, Zinkernagel RM. Natural antibodies and complement link innate and acquired immunity. Immunol Today 2000; 21:624-30.
16. Kim DD, Song WC. Membrane complement regulatory proteins. Clin Immunol 2006; 118:127-36.
17. Kameyoshi Y, Matsushita M, Okada H. Murine membrane inhibitor of complement which accelerates decay of human C3 convertase. Immunology 1989; 68:439-44.
18. Lublin DM, Atkinson JP. Decay-accelerating factor: biochemistry, molecular biology, and function. Annu Rev Immunol 1989; 7:35- 58.
19. Medof ME, Walter EI, Rutgers JL, Knowles DM, Nussenzweig V. Identification of the complement decay-accelerating factor (DAF) on epithelium and glandular cells and in body fluids. J Exp Med 1987; 165:848-64.
20. Fujita T, Inoue T, Ogawa K, Iida K, Tamura N. The mechanism of action of decay-accelerating factor (DAF). DAF inhibits the assembly of C3 convertases by dissociating C2a and Bb. J Exp Med 1987; 166:1221-8.
21. Nicholson-Weller A, March JP, Rosenfeld SI, Austen KF. Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor. Proc Natl Acad Sci USA 1983; 80:5066-70.
22. Ninomiya H, Abe T, Shichishima T, Terasawa T, Fujita T. Decayaccelerating factor (DAF) on the blood cell membranes in patients with paroxysmal nocturnal haemoglobinuria (PNH): measurement by enzyme-linked immunosorbent assay (ELISA). Br J Haematol 1988; 69:81-7.
23. Ninomiya H, Abe T, Fujita T. Prolongation of red-cell life-span by incorporation of decay-accelerating factor (DAF) into red cells of paroxysmal nocturnal haemoglobinuria (PNH). Br J Haematol 1989; 73:132-3.
24. Heeger PS, Lalli PN, Lin F et al. Decay-accelerating factor modulates induction of T cell immunity. J Exp Med 2005; 201:1523-30.
25. Lalli PN, Strainic MG, Lin F, Medof ME, Heeger PS. Decay accelerating factor can control T cell differentiation into IFN-gammaproducing effector cells via regulating local C5a-induced IL-12 production. J Immunol 2007; 179:5793-802.
26. Liu J,Miwa T, Hilliard B et al. The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo. J Exp Med 2005; 201:567-77.
27. Longhi MP,Harris CL,Morgan BP, Gallimore A. Holding T cells in check - a new role for complement regulators? Trends Immunol 2006; 27:102-8.
28. Hamann J,Vogel B, van Schijndel GM, van Lier RA. The seven-span transmembrane receptor CD97 has a cellular ligand (CD55, DAF). J Exp Med 1996; 184:1185-9.
29. Visser L, de Vos AF, Hamann J et al. Expression of the EGF-TM7 receptor CD97 and its ligand CD55 (DAF) in multiple sclerosis. J Neuroimmunol 2002; 132:156-63.
30. Gieske MC, Na GY, Koo Y, Jo M, Curry TE, Jr, Ko C. Decayaccelerating factor in the periovulatory rat ovary. J Endocrinol 2005; 186:303-13.
31. Makidono C, Mizuno M, Nasu J et al. Increased serum concentrations and surface expression on peripheral white blood cells of decay-accelerating factor (CD55) in patients with active ulcerative colitis. J Lab Clin Med 2004; 143:152-8.
32. Gonzalez-Stawinski GV, Tan CD, Smedira NG, Starling RC, Rodriguez ER. Decay-accelerating factor expression may provide immunoprotection against antibody-mediated cardiac allograft rejection. J Heart Lung Transplant 2008; 27:357-61.
33. Shimizu I, Smith NR, Zhao G, Medof E, Sykes M. Decayaccelerating factor prevents acute humoral rejection induced by low levels of anti-alphaGal natural antibodies. Transplantation 2006; 81:95-100.
34. Manez R, Lopez-Pelaez E,Centeno A et al. Transgenic expression in pig hearts of both human decay-accelerating factor and human membrane cofactor protein does not provide an additional benefit to that of human decay-accelerating factor alone in pig-to-baboon xenotransplantation. Transplantation 2004; 78:930-3.
35. Lin F, Fukuoka Y, Spicer A et al. Tissue distribution of products of the mouse decay-accelerating factor (DAF) genes. Exploitation of a Daf1 knock-out mouse and site-specific monoclonal antibodies. Immunology 2001; 104:215-25.
36. Chong KT, Gould JJ, Mims CA. Neutralization of different strains of murine cytomegalovirus (MCMV)-effect of in vitro passage. Arch Virol 1981; 69:95-104.
37. Pomeroy C, Delong D, Clabots C, Riciputi P, Filice GA. Role of interferon-gamma in murine cytomegalovirus infection. J Lab Clin Med 1998; 132:124-33.
38. Watanabe T, Horikawa Y, Sato K, Saito H. Methylcellulose media for plaque assay of murine leukemia virus. J Clin Microbiol 1982; 16:542-4.
39. Tang-Feldman YJ, Wojtowicz A, Lochhead GR, Hale MA, Li Y, Pomeroy C. Use of quantitative real-time PCR (qRT-PCR) to measure cytokine transcription and viral load in murine cytomegalovirus infection. J Virol Methods 2006; 131:122-9.
40. Sobaszek A, Fantoni-Quinton S, Frimat P, Leroyer A, Laynat A, Edme JL. Prevalence of cytomegalovirus infection among health care workers in pediatric and immunosuppressed adult units. J Occup Environ Med 2000; 42:1109-14.
41. Qureshi MH, Garvy BA, Pomeroy C, Inayat MS, Oakley OR. A murine model of dual infection with cytomegalovirus and Pneumocystis carinii: effects of virus-induced immunomodulation on disease progression. Virus Res 2005; 114:35-44.
42. Loberg RD, Day LL, Dunn R, Kalikin LM, Pienta KJ. Inhibition of decay-accelerating factor (CD55) attenuates prostate cancer growth and survival in vivo. Neoplasia 2006; 8:69-78.
43. Bickerstaff AA, Zimmerman PD, Wing BA, Taylor F, Trgovcich J, Cook CH. A flow cytometry-based method for detecting antibody responses to murine cytomegalovirus infection. J Virol Methods 2007; 142:50-8.
44. Krug A, French AR, Barchet W et al. TLR9-dependent recognition of MCMV by IPC and DC generates coordinated cytokine responses that activate antiviral NK cell function. Immunity 2004; 21:107-19.
45. Hawlisch H, Wills-Karp M, Karp CL, Köhl J. The anaphylatoxins bridge innate and adaptive immune responses in allergic asthma. Mol Immunol 2004; 41:123-31.
46. Peng Q, Li K, Sacks SH, Zhou W. The role of anaphylatoxins C3a and C5a in regulating innate and adaptive immune responses. Inflamm Allergy Drug Targets 2009; 8:236-46.
47. Hugli TE. Biochemistry and biology of anaphylatoxins. Complement 1986; 3:111-27.
48. de Medeiros CR, Moreira VA, Pasquini R. Cytomegalovirus as a cause of very late interstitial pneumonia after bone marrow transplantation. Bone Marrow Transplant 2000; 26:443-4.
49. Paya CV. Prevention of cytomegalovirus disease in recipients of solid-organ transplants. Clin Infect Dis 2001; 32:596-603.
50. Ljungman P, Aschan J, Lewensohn-Fuchs I et al. Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients. Transplantation 1998; 66:1330-4.
51. Pillay D,Webster A, Prentice HG,Griffiths PD. Risk factors for viral reactivation following bone marrow transplantation. Ann Hematol 1992; 64 (Suppl):A148-51.
52. Quabeck K. The lung as a critical organ in marrow transplantation. Bone Marrow Transplant 1994; 14 (Suppl. 4):S19-28.
53. Clark JG, Madtes DK, Hackman RC, Chen W, Cheever MA, Martin PJ. Lung injury induced by alloreactive Th1 cells is characterized by host-derived mononuclear cell inflammation and activation of alveolar macrophages. J Immunol 1998; 161:1913-20.
54. Watanabe T, Kawamura T, Kawamura H et al. Intermediate TCR cells in mouse lung: their effector function to induce pneumonitis in mice with autoimmune-like graft-versus-host disease. J Immunol 1997; 158:5805-14.
55. Huisman C, van der Straaten HM, Canninga-van Dijk MR, Fijnheer R, Verdonck LF. Pulmonary complications after T-celldepleted allogeneic stem cell transplantation: low incidence and strong association with acute graft-versus-host disease. Bone Marrow Transplant 2006; 38:561-6.
56. Kradin RL, Divertie MB, Colvin RB et al. Usual interstitial pneumonitis is a T-cell alveolitis. Clin Immunol Immunopathol 1986; 40:224-35.
57. Enelow RI, Mohammed AZ, Stoler MH et al. Structural and functional consequences of alveolar cell recognition by CD8(+) T lymphocytes in experimental lung disease. J Clin Invest 1998; 102:1653-61.
58. Costabel U, Teschler H, Guzman J. Bronchiolitis obliterans organizing pneumonia (BOOP): the cytological and immunocytological profile of bronchoalveolar lavage. Eur Respir J 1992; 5:791-7.
59. Yamada M, Kubo H, Kobayashi S, Ishizawa K, Sasaki H. Interferongamma: a key contributor to hyperoxia-induced lung injury in mice. Am J Physiol Lung Cell Mol Physiol 2004; 287:L1042-7.
60. Stager S, Alexander J, Kirby AC et al. Natural antibodies and complement are endogenous adjuvants for vaccine-induced CD8+ T-cell responses. Nat Med 2003; 9:1287-92.
61. Suresh M,Molina H, Salvato MS,Mastellos D, Lambris JD, Sandor M. Complement component 3 is required for optimal expansion of CD8 T cells during a systemic viral infection. J Immunol 2003; 170:788-94.
62. Spiller OB,Morgan BP, Tufaro F, Devine DV. Altered expression of host-encoded complement regulators on human cytomegalovirusinfected cells. Eur J Immunol 1996; 26:1532-8.
63. Thornton BP, Vetvicka V, Ross GD. Natural antibody and complement-mediated antigen processing and presentation by B lymphocytes. J Immunol 1994; 152:1727-37.
64. Cherukuri A, Cheng PC, Pierce SK. The role of the CD19/CD21 complex in B cell processing and presentation of complementtagged antigens. J Immunol 2001; 167:163-72.
65. Westall GP, Snell GI, McLean C, Kotsimbos T, Williams T, Magro C. C3d and C4d deposition early after lung transplantation. J Heart Lung Transplant 2008; 27:722-8.
66. Magro CM, Abbas AE, Seilstad K, Pope-Harman AL, Nadasdy T, Ross P, Jr. C3d and the septal microvasculature as a predictor of chronic lung allograft dysfunction. Hum Immunol 2006; 67:274- 83.
67. Kopf M, Abel B, Gallimore A, Carroll M, Bachmann MF. Complement component C3 promotes T-cell priming and lung migration to control acute influenza virus infection. Nat Med 2002; 8:373-8.
68. Strainic MG, Liu J, Huang D et al. Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells. Immunity 2008; 28:425-35.
69. Lalli PN, Strainic MG, Yang M, Lin F, Medof ME, Heeger PS. Locally produced C5a binds to T cell-expressed C5aR to enhance effector T-cell expansion by limiting antigen-induced apoptosis. Blood 2008; 112:1759-66.